How effective are the COVID-19 vaccines? A Bayesian analysis
Wibbens, P. D.
Show abstract
This short paper reports a Bayesian analysis of the publicly available COVID-19 trial results. The analysis casts some doubts on whether the half+full dose regime of the AstraZeneca COVID-19 vaccine is truly more effective than the 2x full dose regime. The 95% posterior interval for the efficacy of the half+full dose regime is 66.6-96.3%, while for the 2x full dose regime it is 39.0-74.8%. Hence, it is possible that in both dosage regimes the vaccine has similar efficacy, around 70%. The estimated efficacy for the Pfizer vaccine is 89.9-97.4% and for Moderna 86.3-97.5%. These results should be interpreted with care though, since this analysis does not account for differences in for instance trial population, COVID-19 testing, and storage requirements for the various vaccines.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Using numerical modelling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample 94%
- Evaluating the effects of vaccine rollout policies in European countries: A simulation study 93%
- A method of back-calculating the log odds ratio and standard error of the log odds ratio from the reported group-level risk of disease 92%
Similar papers in this journal
- Analysis of host immunological response of adenovirus-based COVID-19 vaccines 93%
- Cost-effectiveness of quadrivalent versus trivalent inactivated influenza vaccines for the Portuguese elderly population 91%
- Modeling the impact of COVID-19 vaccination in Lebanon: A call to speed-up vaccine roll out 91%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.